Brought to you by 
Acetylon allies with Harvard University, Dana-Farber
24 Feb 2023
Executive Summary
Acetylon Pharmaceuticals Inc. (cancer, autoimmune diseases, and musculoskeletal disorders) has licensed exclusive rights to technology, methodology, and compounds from Harvard University and the Dana-Farber Cancer Institute related to histone deacetylase inhibitors for neurological and inflammatory diseases and cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acetylon allies with Harvard University, Dana-Farber
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice